No Data
Express News | Invivyd- Sars-Cov-2 Mab Candidate, Vyd2311 Shows Continued in Vitro Neutralization Activity in Pseudovirus Assays Against Kp.1.1 Flirt, Kp.3 Variants
Express News | Invivyd: Pseudovirus in Vitro Neutralization Data Show Continued Neutralizing Activity of Vyd222 (Pemivibart) Against Kp.1.1 Flirt & Kp.3 Sars-Cov-2
Express News | Invivyd Announces Antiviral Activity of Vyd222 (Pemivibart) Against Sars-Cov-2 Kp.1.1 Flirt & Kp.3 Variants
Invivyd to Participate at the Jefferies Global Healthcare Conference
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management
Invivyd(IVVD.US) Director Sells US$186.57K in Common Stock
$Invivyd(IVVD.US)$ Director MCGUIRE TERRANCE sold 112.38K shares of common stock on May 29, 2024 at an average price of $1.6602 for a total value of $186.57K.Source: Announcement What is statement of
Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment